Wednesday , April 24 2019

Home / Business & Investment News / Tsai Chiang, Renowned in the Field of Neurology, Engaged by Braincure-Biotech.com as Special Advisor

Tsai Chiang, Renowned in the Field of Neurology, Engaged by Braincure-Biotech.com as Special Advisor

Related eBooks

Tsai Chiang, Renowned in the Field of Neurology, Engaged by Braincure-Biotech.com as Special Advisor

Braincure is an early-stage research and development company focused on evaluating a novel approach to the treatment of Alzheimer s disease

Online PR News – 09-November-2015 – Braincure-Biotech.com today announced that the company has engaged Tsai Chiang, renowned pioneer in the field of neurology, entrepreneur and present President of Neurology Committee, as a special advisor. Mr. Chiang will serve as an invaluable resource in supporting rapid growth for the company as neurology stimulation, the focus of Braincures research, is formally launched for study in Asia, Europe and then the United States.

Braincure Biotech is focused on evaluating an approach to Alzheimer s disease treatment that has been clinically recognized, but never before studied in a clinically significant way. The potential impact on patients and their families is extremely significant, said Mr. Chiang. Serving as a special advisor to help drive corporate growth affords me yet another opportunity to reinforce the focus of serving others in a broad range of capacities as a public servant, as an entrepreneur and most recently, as President and CEO of a large Pharmaceutical conglomerate, where technology was applied to humanitarian purposes aswell.

Suhon Horng, president and CEO of Braincure Biotech stated, We couldnt be happier to have the benefit of Mr. Chiangs experience and expertise as the company moves into initial clinical trials for its neurological stimulation medical device in Asia. These outcomes have the potential to demonstrate that prior clinical observation and analysis of the effects of neurological stimulation on cognitive function in Alzheimer s disease patients is measurable and sustainable, and therefore offers hope for millions of people, and their families, where there was none before. With the Mr. Chiangs support and input we are working to move forward quickly and effectively.

About Braincure Biotech
Braincure-Biotech.com is a state-of-the-art technology research company that uses discoveries in neuroimmunolgy and human genetics to develop novel therapeutics for Alzheimers disease, other forms of dementia, and mechanistically similar disorders. Braincure Biotechs strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. The goal of the firm is to discover and develop novel, disease modifying therapies for dementia and mechanistically similar disorders. The highly professional and acclaimed team of scientists maintains an innovative and motivating environment in which every employee has the possibility to contribute to our joint success and to grow individually.

Company Contact Information
Braincure-Biotech-com
http://www.braincure-biotech.com/
+886
 

Check Also

Consider Kirkland Lake Gold (KL), A Gold Mining Growth Stock

This week we are looking at another of the Investor’s Business Daily (IBD) Top 50 List companies.  We use this list in one of our options portfolios to spot outperforming stocks and place option spreads that take advantage of the momentum. Last week was a great one for the market (SPY up 2.6%) and an even better one for the Terry’s Tips 8 actual option portfolios.  Every one made gains, and the composite average picked up 11%, a record we are quite proud of.  Terry Consider Kirkland Lake Gold (KL), A Gold Mining Growth Stock The Investor’s Business Daily recently posted an article which started out by stating “Gold might not come to mind first when you think of growth stocks” which is very true.  Take a look at this article for the full write up and the reasoning behind why they see growth potential in this stock.  Also check out Kirkland Lake Gold Receives Consensus Rating of “Buy” from Analysts.

Leave a Reply

Your email address will not be published. Required fields are marked *

css.php